MedPath

Sleep Apnea and Tromboembolic Disease

Conditions
Sleep Apnea Syndromes
Venous Thromboembolism
Registration Number
NCT00501358
Lead Sponsor
Sociedad Española de Neumología y Cirugía Torácica
Brief Summary

There is some evidence for a hypercoagulable state in sleep apnea-hipopnea syndrome (SAHS), which could play a role in the increased cardiovascular morbility and mortality. Respiratory alterations (hypoxia, hypoxia- reoxygenation) and sleep fragmentation that these patients suffer during the sleep may induce modifications in clotting-fibrinolisis factors that may be a risk factor for venous thromboembolism (VTE).

OBJECTIVES:To calculate and compare the prevalence of sleep apnea-hipopnea syndrome in patients with venous thromboembolism with a gender, aged and BMI matched control group. Assessment of the association between SAHS and other risk factors for VTE. To compare clotting- fibrinolisis patterns, sleep parameters, blood pressure and pulmonary arterial obstruction index in patients with SAHS and VTE and those ones without SAHS.

Detailed Description

DESIGN: Case-control study.

METHODS: 133 SAHS patients and 133 controls will be studied. The study includes:

a) medical history; b) anthropometric variables (weight, height, body mass index, Mallampati index); c) sleepiness tested by Epworth scale; d) London Chest Activity of Daily Living Scale; e) conventional polysomnography (PSG); f) testing: clotting-fibrinolisis factors (factor V, VII, VIII; C and S protein, plasminogen tissular activator (t-PA) and inhibitor of plasminogen activator (PAI-1); g) d-dimer and thrombin-antithrombin III complex; h) basic biochemical profile and hemograma; i) Pulmonary artery obstruction index.

Recruitment & Eligibility

Status
UNKNOWN
Sex
All
Target Recruitment
Not specified
Inclusion Criteria
  • Case group:
  • Pulmonary embolism diagnosed by CT Pulmonary Angiography.
  • Control group:
  • randomly selected from among patients in two primary health care centers in Mallorca without tromboembolic disease
Exclusion Criteria
  • Refusal to sign informed consent.
  • Expected survival less than 12 months
  • Long-term oxygen therapy
  • Hospital admission in the previous two months.
  • Familiar thrombophilia

Study & Design

Study Type
OBSERVATIONAL
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (1)

Hospital Universitario Son Dureta

🇪🇸

Palma de Mallorca, Baleares, Spain

© Copyright 2025. All Rights Reserved by MedPath